Quality of online information about phase I clinical cancer trials in Sweden, Denmark and Norway

被引:3
作者
Godskesen, Tove E. [1 ,2 ]
Fernow, Josepine [2 ]
Eriksson, Stefan [2 ]
机构
[1] Ersta Skondal Bracke Univ Coll, Dept Hlth Care Sci, Stockholm, Sweden
[2] Uppsala Univ, Ctr Res Eth & Bioeth, Uppsala, Sweden
关键词
cancer; comprehension; ethics; informed consent; Internet; phase I clinical trials;
D O I
10.1111/ecc.12937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients increasingly search for online information about clinical trials. Little is known about the quality and readability of the information in these databases. Therefore, the aim of this study was to assess the quality and readability of online information available to the public on phase I clinical cancer trials in Sweden, Denmark and Norway. A qualitative content analysis was made of 19 online trial descriptions from three public websites in Sweden, Denmark and Norway, and the readability of the documents was tested. Both the quality of the content and the readability scores were best for the Danish information. The Swedish texts were very short and were the least readable. Overall, the quality of the information was highly variable and nearly all the documents were misleading in part. Furthermore, the descriptions provided almost no information about possible adverse effects or disadvantages of study participation. This study highlights a communication problem and proposes new ways of presenting studies that are less suggestive of positive outcomes, arguing that we should be more careful to include information about adverse effects, and that the use of simple measures like readability testing can be useful as an indicator of text quality.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Quality of Online Information About Irritable Bowel Syndrome
    Levine, Louis
    Akhtar, Nabeel
    Glasgow, Lori-Ann
    Thompson, Elizabeth
    Razeghi, Sanam
    Ouyang, Ann
    PRACTICAL GASTROENTEROLOGY, 2020, 44 (03) : 14 - 23
  • [22] Patient representatives' views on patient information in clinical cancer trials
    Dellson, Pia
    Nilbert, Mef
    Carlsson, Christina
    BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [23] Psychological distress in patients with metastatic cancer enrolling on phase I clinical trials
    Hunt, Alexandra
    Handorf, Elizabeth
    Blau, Matthew
    Chertock, Yana
    Fang, Carolyn
    Hall, Michael J.
    Jain, Rishi
    JOURNAL OF CANCER SURVIVORSHIP, 2021, 15 (03) : 398 - 402
  • [24] Psychological distress in patients with metastatic cancer enrolling on phase I clinical trials
    Alexandra Hunt
    Elizabeth Handorf
    Matthew Blau
    Yana Chertock
    Carolyn Fang
    Michael J Hall
    Rishi Jain
    Journal of Cancer Survivorship, 2021, 15 : 398 - 402
  • [25] Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
    Nurgat, ZA
    Craig, W
    Campbell, NC
    Bissett, JD
    Cassidy, J
    Nicolson, MC
    BRITISH JOURNAL OF CANCER, 2005, 92 (06) : 1001 - 1005
  • [26] Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
    Z A Nurgat
    W Craig
    N C Campbell
    J D Bissett
    J Cassidy
    M C Nicolson
    British Journal of Cancer, 2005, 92 : 1001 - 1005
  • [27] Optimal biological dose: a systematic review in cancer phase I clinical trials
    J. Fraisse
    D. Dinart
    D. Tosi
    C. Bellera
    C. Mollevi
    BMC Cancer, 21
  • [28] Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials
    Molfino, Alessio
    Amabile, Maria Ida
    Giorgi, Antonella
    Monti, Massimo
    D'Andrea, Vito
    Muscaritoli, Maurizio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 733 - 740
  • [29] Communicating About Phase I Trials: Objective Disclosures Are Only A First Step
    Flamm, Anne Lederman
    Pentz, Rebecca D.
    ONCOLOGIST, 2012, 17 (04) : 466 - 468
  • [30] Optimal biological dose: a systematic review in cancer phase I clinical trials
    Fraisse, J.
    Dinart, D.
    Tosi, D.
    Bellera, C.
    Mollevi, C.
    BMC CANCER, 2021, 21 (01)